title: [Does aluminum affect the effectiveness of human recombinant erythropoietin in the treatment of anemia in dialyzed patients?].
abstract: In five female patients with chronic renal failure who had regular dialyzation treatment it was revealed that hyperaluminaemia reduces the effect of erythropoietin. In view of the high cost of this drug it is reasonable to maintain the aluminium value at the lowest levels.
authors.affiliation: Interní oddĕlení Strahov fakultní nemocnice 2 s FP UNZ, Praha.
authors.forename: S
authors.initials: S
authors.lastname: Sulková
authors.forename: Z
authors.initials: Z
authors.lastname: Laurincová
authors.forename: J
authors.initials: J
authors.lastname: Kvasnicka
mesh_terms: D000535:Aluminum / Q000097:blood*; D000740:Anemia / Q000097:blood / Q000209:etiology / Q000628:therapy*; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D011994:Recombinant Proteins; D006435:Renal Dialysis / Q000009:adverse effects*
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin; D000535:Aluminum
vernacular_title: Ovlivnuje aluminium úcinnost lidského rekombinantního erytropoetinu pri lécbĕ anémie dialyzovaných nemocných?